CJ Bioscience, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2009-12-09
- Employees
- 137
- Market Cap
- -
- Website
- http://www.cjbioscience.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- NSCLCHNSCCMelanomaAdvanced Solid TumorMetastatic CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- CJ Bioscience, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05877430
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
News
No news found